The 5 analysts offering 12-month price forecasts for Arbutus Biopharma Corp have a median target of 6.00, with a high estimate of 9.00 and a low estimate of 4.00. The median estimate represents a +210.88% increase from the last price of 1.93.
The current consensus among 5 polled investment analysts is to Buy stock in Arbutus Biopharma Corp. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.13
Reporting Date Nov 03
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.